A Double-Blind, Placebo Controlled-Trial of a Probiotic Strain Lactobacillus sakei Probio-65 for the Prevention of Canine Atopic Dermatitis.
- 2015-11-28
- Journal of Microbiology and Biotechnology 25(11)
- Hye-iin Kim
- I. Rather
- Hyunwook Kim
- Sungsoo Kim
- Taeeun Kim
- Jaeyoung Jang
- Jimin Seo
- Jeongheui Lim
- Yong-Ha Park
- PubMed: 26282691
- DOI: 10.4014/jmb.1506.06065
Abstract
Canine atopic dermatitis (CAD) is a ubiquitous, chronic inflammatory skin disorder prevalent in dogs, which results in production of abnormal levels of IgE antibodies in reciprocation to an allergen challenge. In this study, administration of the probiotic strain Lactobacillus sakei probio-65 for 2 months significantly reduced the disease severity index in experimental dogs diagnosed with CAD. In addition, one month pre-medication of L. sakei probio-65 revealed significant difference in the PVAS score in experimental dogs for both probio-65 and placebo groups. However, post 2 months treatment resulted in a significant decrease in the CASESI score values in the probio-65-treated group (p < .0.06).
Keywords: Canine atopic dermatitis; Lactobacillus sakei; probiotics; skin disorder.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Lactobacillus sakei proBio65 | Reduced CASESI Score in Canine Atopic Dermatitis | Beneficial | Moderate |
Lactobacillus sakei proBio65 | Reduced Disease Severity in Canine Atopic Dermatitis | Beneficial | Moderate |
Lactobacillus sakei proBio65 | Reduced PVAS Score in Canine Atopic Dermatitis | Beneficial | Moderate |